Literature DB >> 8429216

Optimisation of small-scale coupling of A5B7 monoclonal antibody to carboxypeptidase G2.

R G Melton1, J M Boyle, G T Rogers, P Burke, K D Bagshawe, R F Sherwood.   

Abstract

Conjugates of F(ab')2 fragment of the monoclonal antibody A5B7 coupled to carboxypeptidase G2 (CPG2) have been produced using the heterobifunctional reagents 2-mercapto-[S-acetyl]acetic acid, N-hydroxysuccinimide ester (SATA) and m-maleimidobenzoyl-N-hydroxysuccinimide ester (SMPB). The effect of various levels of modifying reagent on enzyme activity and antigen binding activity were determined, and it was shown that whilst CPG2 is relatively sensitive to modification, insertion of three maleimide groups per CPG2 resulted in the loss of 30% of enzyme activity; A5B7 F(ab')2 was insensitive to modification, little or no activity being lost. The coupling efficiency of the reaction was shown to be fairly constant over a wide range of substitution levels. There was thus no advantage to be gained in using high substitution levels, which may result in loss of enzyme activity. The formation of undesired high molecular weight aggregates could be controlled by adjustment of the protein concentration during the final coupling step.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8429216     DOI: 10.1016/0022-1759(93)90257-8

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  9 in total

Review 1.  Antibody-directed enzyme prodrug therapy.

Authors:  K D Bagshawe
Journal:  Clin Pharmacokinet       Date:  1994-11       Impact factor: 6.447

2.  Human immune response to monoclonal antibody-enzyme conjugates in ADEPT pilot clinical trial.

Authors:  S K Sharma; K D Bagshawe; R G Melton; R F Sherwood
Journal:  Cell Biophys       Date:  1992 Aug-Dec

3.  Antibody-directed enzyme prodrug therapy (ADEPT). A three-phase study in ovarian tumor xenografts.

Authors:  S K Sharma; J A Boden; C J Springer; P J Burke; K D Bagshawe
Journal:  Cell Biophys       Date:  1994

4.  Altered biodistribution of an antibody--enzyme conjugate modified with polyethylene glycol.

Authors:  E A Eno-Amooquaye; F Searle; J A Boden; S K Sharma; P J Burke
Journal:  Br J Cancer       Date:  1996-06       Impact factor: 7.640

5.  Measurement of the critical DNA lesions produced by antibody-directed enzyme prodrug therapy (ADEPT) in vitro, in vivo and in clinical material.

Authors:  S D Webley; R J Francis; R B Pedley; S K Sharma; R H Begent; J A Hartley; D Hochhauser
Journal:  Br J Cancer       Date:  2001-06-15       Impact factor: 7.640

Review 6.  Microbial cytosine deaminase is a programmable anticancer prodrug mediating enzyme: antibody, and gene directed enzyme prodrug therapy.

Authors:  Ashraf S A El-Sayed; Nabil Z Mohamed; Marwa A Yassin; Mahmoud M Amer; Reyad El-Sharkawy; Nesma El-Sayed; Mostafa G Ali
Journal:  Heliyon       Date:  2022-09-16

7.  Plasma clearance of an antibody--enzyme conjugate in ADEPT by monoclonal anti-enzyme: its effect on prodrug activation in vivo.

Authors:  G T Rogers; P J Burke; S K Sharma; R Koodie; J A Boden
Journal:  Br J Cancer       Date:  1995-12       Impact factor: 7.640

8.  Anti-tumour effects of an antibody-carboxypeptidase G2 conjugate in combination with phenol mustard prodrugs.

Authors:  D C Blakey; D H Davies; R I Dowell; S J East; P J Burke; S K Sharma; C J Springer; A B Mauger; R G Melton
Journal:  Br J Cancer       Date:  1995-11       Impact factor: 7.640

9.  Modifying an immunogenic epitope on a therapeutic protein: a step towards an improved system for antibody-directed enzyme prodrug therapy (ADEPT).

Authors:  A Mayer; S K Sharma; B Tolner; N P Minton; D Purdy; P Amlot; G Tharakan; R H J Begent; K A Chester
Journal:  Br J Cancer       Date:  2004-06-14       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.